Breakthrough Optogenetic Therapy UGX-201 Shows Promise for Advanced Retinitis Pigmentosa

Highlights

• UGX-201 optogenetic therapy shows a favorable safety profile in advanced nonsyndromic retinitis pigmentosa (RP) patients over 52 weeks.
• Significant improvement in best-corrected visual acuity (BCVA) and patient-reported visual function observed in patients with light perception (LP).
• Restoration of light perception achieved and sustained in three patients previously with no light perception (NLP).
• UGX-201 represents a novel, mutation-independent treatment approach targeting retinal ganglion cells for vision restoration in advanced RP.

Study Background

Retinitis pigmentosa (RP) constitutes a heterogeneous group of inherited retinal dystrophies characterized by progressive photoreceptor degeneration leading to vision loss and eventual blindness. Advanced-stage RP patients often reach profound visual impairment, including complete loss of light perception (NLP), for which no effective treatment currently exists. The genetic diversity underlying nonsyndromic RP limits mutation-specific therapeutic strategies. Optogenetic therapy, which enables restoration of light sensitivity by genetically modifying surviving inner retinal neurons to express photosensitive proteins, offers a mutation-independent approach to recover visual function in late-stage RP.

UGX-201 is an investigational gene therapy using an adeno-associated virus 2 type 7m8 variant vector to deliver a recombinant chimeric opsin selectively to retinal ganglion cells (RGCs). By rendering RGCs directly photosensitive, UGX-201 aims to bypass dysfunctional or lost photoreceptors and restore functional vision. This first-in-human exploratory clinical trial was designed to evaluate the safety, tolerability, and preliminary efficacy of UGX-201 in patients with advanced nonsyndromic RP.

Study Design

This open-label, nonrandomized, single-center investigator-initiated clinical trial (ChiCTR2200062174) enrolled nine patients with advanced nonsyndromic RP. Participants were stratified into two cohorts based on baseline visual function: six patients with residual light perception (LP cohort) and three with no light perception (NLP cohort). Each patient received a single intravitreal injection of UGX-201 at a dose of 1.5 × 10¹¹ viral genomes per treated eye.

Follow-up was conducted over at least 52 weeks with comprehensive ophthalmic and systemic safety evaluations, including adverse event (AE) monitoring. Efficacy assessments included best-corrected visual acuity (BCVA) measured by the Freiburg Visual Acuity and Contrast Test (FrACT), full-field stimulus threshold (FST) testing to quantify light sensitivity, and patient-reported outcomes via the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25).

Key Findings

Safety and Tolerability

Throughout the 52-week follow-up, no serious ocular or systemic adverse events related to UGX-201 were observed. The treatment was well-tolerated, with no reports of inflammation or vector-related complications, underscoring an encouraging safety profile.

Efficacy in Light Perception Cohort

In the six patients retaining light perception, BCVA in treated eyes improved by a mean of 0.30 logMAR at Week 52, indicative of a measurable gain in visual acuity. Notably, one participant demonstrated substantial improvement in full-field stimulus threshold testing, reflecting enhanced retinal light sensitivity. Additionally, the composite NEI VFQ-25 score improved by 3.72 points at Week 52, translating into meaningful patient-perceived visual function enhancement.

Efficacy in No Light Perception Cohort

All three patients classified as NLP at baseline experienced restoration of light perception in the treated eye at various time points: Week 2, Week 4, and Week 24, respectively. Importantly, two of these patients maintained light perception at Week 52, signifying sustained therapeutic benefit. This restoration represents a groundbreaking advance for patients with previously untreatable advanced vision loss.

Expert Commentary

The results from this dose-escalation exploratory trial position UGX-201 as a promising first-in-class optogenetic therapy for advanced nonsyndromic RP, overcoming limitations of mutation-specific treatments. Its safety and tolerability support further clinical development. Notably, meaningful improvements in visual acuity and function were observed even in severely vision-impaired participants, including those with no baseline light perception, illustrating the biological plausibility of reactivating retinal ganglion cells as novel photoreceptors.

Nonetheless, this study’s limitations include the small sample size and lack of placebo control or randomization, which restrict definitive efficacy conclusions. Longer-term studies with larger, controlled cohorts are required to validate and contextualize these findings. Moreover, functional vision improvements need to be correlated with real-world visual tasks to ascertain patient quality of life impact comprehensively.

Conclusion

UGX-201 optogenetic therapy showed a favorable safety profile and was well-tolerated in patients with advanced nonsyndromic retinitis pigmentosa. Both patients with residual light perception and those without experienced sustained, clinically meaningful improvements in visual function. This mutation-independent therapeutic approach targeting retinal ganglion cells holds substantial potential to transform management of advanced retinal degenerative diseases characterized by photoreceptor loss. Ongoing and future trials should aim to optimize dosing, assess durability, and evaluate functional vision outcomes to support regulatory approval and clinical adoption.

Funding and Clinical Trial Registration

This investigator-initiated clinical trial was registered under ChiCTR2200062174. Details of study funding were not provided in the publication.

References

• Han X, Zhu Z, Song Z, et al. Optogenetic Therapy With UGX-201 in Advanced Nonsyndromic Retinitis Pigmentosa: Safety and Efficacy From an Exploratory Clinical Trial. Am J Ophthalmol. 2026 Apr 8;287:222-236. PMID: 41962791.
• Sahel JA, Marazova K, Audo I. Clinical characteristics and current therapies for inherited retinal degenerations. Cold Spring Harb Perspect Med. 2015 Sep 1;5(9):a017111.
• Garcia M, Pan X, Shah K, et al. Optogenetic approaches for vision restoration. Prog Retin Eye Res. 2020 Jan;74:100768.